British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca (LSE:AZN)(STO:AZN)(Nasdaq:AZN) announced on Monday that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, demonstrated statistically significant results in the CALYPSO Phase III trial, meeting the primary endpoint in adults with chronic hypoparathyroidism (HypoPT) after 24 weeks.
This primary endpoint involved normalisation of albumin-adjusted serum calcium levels and independence from active vitamin D and oral calcium therapy. HypoPT, a rare endocrine disorder affecting over 200,000 people in the United States and the European Union, is caused by a deficiency of PTH, leading to dysregulated calcium and phosphate levels. Eneboparatide was well tolerated and all patients will continue treatment in an ongoing long-term extension period for up to 52 weeks. Efficacy and safety data will be fully analysed at 52 weeks.
The CALYPSO trial was a global, randomised, double-blind, placebo-controlled study that included 202 patients receiving standard of care, who were randomly assigned to receive either eneboparatide or placebo. The primary efficacy endpoint focused on the proportion of patients achieving normal serum calcium levels and discontinuation of standard treatment. Secondary endpoints included normalisation of 24-hour urinary calcium in hypercalciuria patients and patient-reported outcomes reflecting physical symptoms and quality of life. Eneboparatide is designed to restore PTH function, supporting kidney and bone health and has received fast track and orphan drug designations from the FDA and EMA for HypoPT treatment. Alexion, AstraZeneca Rare Disease is committed to addressing rare disease challenges and continues to expand its portfolio globally.
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025